Volume 9 — August 09, 2012
CME ACTIVITY
Continuation With Statin Therapy and the Risk of Primary Cancer: A Population-Based Study
| Cases of Cancer | Hazard Ratio (95% Confidence Interval) |
|---|---|
| Women (n = 4,095) | 1 (0.99–1.01) |
| Men (n = 4,567) | 0.98 (0.97–0.99) |
| Age 21–49 y (n = 696) | 0.99 (0.97–1.02 |
| Age 50–65 y (n = 4,164) | 0.98 (0.97–0.99) |
| Age ≥66 (n = 3,802) | 0.98 (0.97–0.99) |
| Low statin efficacy (n = 3,712) | 0.99 (0.98–1.01) |
| Medium statin efficacy (n = 4,267) | 0.99 (0.98–1.01) |
| High statin efficacy (n = 583) | 0.95 (0.92–0.97) |
Figure 1. Proportional effects of persistence with statin therapy on reduction of risk for overall cancer per 10% of follow-up days covered with statins. Squares indicate adjusted hazard ratios for all covariates listed in Table 2. Horizontal lines indicate 95% confidence intervals. The 3 statin efficacy levels were created on the basis of expected amounts of low-density lipoprotein reduction from baseline.
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions.
